Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress

Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical programs while continuing efforts to strengthen its financing position. The biotech company said it recently reported positive expanded Phase 2 data for its SkinJect Doxorubicin Microneedle Array treatment for nodular basal cell carcinoma, including what it described as registrational-grade clearance rates in the 200-microgram treatment cohort.